Description:
- Therapeutic peptide targets RAS signal transduction pathways, and can be utilized for indications associated with these pathways
Abstract
USC researchers have discovered that the novel oral formulation of Nle3-A(1-7) has the unexpected result that shows significantly more potent therapeutic effects than corresponding compositions. This oral formulation is more convenient and palatable to deliver compared to injections in systemic diseases and can be formulated into tablets, gelcaps, softgels, and capsules.
Benefit
- Nle3-A(1-7) oral formulation has a better side effect and tolerability profile than non-oral peptide formulation
- Nle3-A(1-7) oral formulation can be formulated with other therapeutic agents
Market Application
Therapeutic peptides for applications in medicine and biotechnology are highly beneficial to treat major disease areas such as diabetes, oncology, and metabolic disorders. The global peptide market is expected to increase up to $25.4 billion in 2018. The synthetic peptide Nle3-A(1-7) is a peptide which can activate the Renin Angiotensin System (RAS), having a direct effect on cardiovascular homeostasis, wound healing, hematopoiesis, and reduction of chemotherapy associated bone marrow suppression. Delivery of Nle3-A(1-7) as an oral formulation can provide a highly selective, efficacious, safe and well tolerated route of drug delivery to address these indications.
Publications
Papinska AM, et al., Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling. Pharmacol Res. 2016 May; 107:372-80.
Other
- In vitro data validated; in vivo efficacy data being validated
- Available for exclusive license
Status: US patent issued 10,987,403